Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene BRAF
Variant V600D
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions BRAF V600D (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600D confers a gain of function to the Braf protein as demonstrated by increased kinase activity, downstream signaling, and the ability to transform cells in vitro (PMID: 15035987).
Associated Drug Resistance
Category Variants Paths

BRAF mutant BRAF act mut BRAF V600D

BRAF mutant BRAF V600X BRAF V600D

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_004333.6
gDNA chr7:g.140753335_140753336delTGinsAC
cDNA c.1799_1800delTGinsAC
Protein p.V600D
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_004333 chr7:g.140753335_140753336delCAinsGT c.1799_1800delTGinsAC p.V600D RefSeq GRCh38/hg38
NM_001354609.1 chr7:g.140753335_140753336delTGinsAC c.1799_1800delTGinsAC p.V600D RefSeq GRCh38/hg38
NM_004333.5 chr7:g.140753335_140753336delTGinsAC c.1799_1800delTGinsAC p.V600D RefSeq GRCh38/hg38
NM_001378474.1 chr7:g.140753335_140753336delTGinsAC c.1799_1800delTGinsAC p.V600D RefSeq GRCh38/hg38
NM_004333.6 chr7:g.140753335_140753336delTGinsAC c.1799_1800delTGinsAC p.V600D RefSeq GRCh38/hg38
NM_001354609.2 chr7:g.140753335_140753336delTGinsAC c.1799_1800delTGinsAC p.V600D RefSeq GRCh38/hg38
NM_001378468.1 chr7:g.140753335_140753336delTGinsAC c.1799_1800delTGinsAC p.V600D RefSeq GRCh38/hg38
XM_005250045 chr7:g.140753335_140753336delCAinsGT c.1799_1800delTGinsAC p.V600D RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02693535 Phase II Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Recruiting USA 0
NCT04201457 Phase Ib/II Hydroxychloroquine + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Recruiting USA 0
NCT03915951 Phase II Binimetinib + Encorafenib An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer Active, not recruiting USA | NLD | ITA | ESP 1
NCT01659151 Phase II Aldesleukin Fludarabine Vemurafenib Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma Active, not recruiting USA 0
NCT02257424 Phase Ib/II Dabrafenib + Hydroxychloroquine + Trametinib Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM) Completed USA 0
NCT04074096 Phase II Binimetinib + Encorafenib + Pembrolizumab Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB) Active, not recruiting FRA 0
NCT03839342 Phase II Binimetinib + Encorafenib Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) Active, not recruiting CAN 0